BIOMAT Database Logo BIOMAT Database Logo

Identification of dipeptidyl peptidase IV inhibitors: virtual screening, synthesis and biological evaluation. 2014

Junhao Xing, and Qing Li, and Shengping Zhang, and Haomiao Liu, and Leilei Zhao, and Haibo Cheng, and Yuan Zhang, and Jinpei Zhou, and Huibin Zhang
Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, China.

Inhibition of dipeptidyl peptidase IV is an important approach for the treatment of type-2 diabetes. In this study, we reported a multistage virtual screening workflow that integrated 3D pharmacophore models, structural consensus docking, and molecular mechanics/generalized Born surface area binding energy calculation to identify novel dipeptidyl peptidase IV inhibitors. After screening our in-house database, two hit compounds, HWL-405 and HWL-892, having persistent high performance in all stages of virtual screening were identified. These two hit compounds together with several analogs were synthesized and evaluated for in vitro inhibition of dipeptidyl peptidase IV. The experimental data indicated that most designed compounds exhibited significant dipeptidyl peptidase IV inhibitory activity. Among them, compounds 35f displayed the greatest potency against dipeptidyl peptidase IV in vitro with the IC50 value of 78 nm. In an oral glucose tolerance test in normal male Kunming mice, compound 35f reduced blood glucose excursion in a dose-dependent manner.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D008297 Male Males
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D012372 ROC Curve A graphic means for assessing the ability of a screening test to discriminate between healthy and diseased persons; may also be used in other studies, e.g., distinguishing stimuli responses as to a faint stimuli or nonstimuli. ROC Analysis,Receiver Operating Characteristic,Analysis, ROC,Analyses, ROC,Characteristic, Receiver Operating,Characteristics, Receiver Operating,Curve, ROC,Curves, ROC,ROC Analyses,ROC Curves,Receiver Operating Characteristics
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D017434 Protein Structure, Tertiary The level of protein structure in which combinations of secondary protein structures (ALPHA HELICES; BETA SHEETS; loop regions, and AMINO ACID MOTIFS) pack together to form folded shapes. Disulfide bridges between cysteines in two different parts of the polypeptide chain along with other interactions between the chains play a role in the formation and stabilization of tertiary structure. Tertiary Protein Structure,Protein Structures, Tertiary,Tertiary Protein Structures

Related Publications

Junhao Xing, and Qing Li, and Shengping Zhang, and Haomiao Liu, and Leilei Zhao, and Haibo Cheng, and Yuan Zhang, and Jinpei Zhou, and Huibin Zhang
Identification of diverse dipeptidyl peptidase IV inhibitors via structure-based virtual screening.
September 2012, Journal of molecular modeling,
Junhao Xing, and Qing Li, and Shengping Zhang, and Haomiao Liu, and Leilei Zhao, and Haibo Cheng, and Yuan Zhang, and Jinpei Zhou, and Huibin Zhang
Dipeptidyl peptidase IV: development, design, synthesis and biological evaluation of inhibitors.
January 1994, Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie,
Junhao Xing, and Qing Li, and Shengping Zhang, and Haomiao Liu, and Leilei Zhao, and Haibo Cheng, and Yuan Zhang, and Jinpei Zhou, and Huibin Zhang
Synthesis and evaluation of thiouracil derivatives as dipeptidyl peptidase IV inhibitors.
February 2013, Chemical biology & drug design,
Junhao Xing, and Qing Li, and Shengping Zhang, and Haomiao Liu, and Leilei Zhao, and Haibo Cheng, and Yuan Zhang, and Jinpei Zhou, and Huibin Zhang
Synthesis and biological activity of sulphostin analogues, novel dipeptidyl peptidase IV inhibitors.
February 2005, Bioorganic & medicinal chemistry,
Junhao Xing, and Qing Li, and Shengping Zhang, and Haomiao Liu, and Leilei Zhao, and Haibo Cheng, and Yuan Zhang, and Jinpei Zhou, and Huibin Zhang
Synthesis and evaluation of pyrazolidine derivatives as dipeptidyl peptidase IV (DP-IV) inhibitors.
March 2005, Bioorganic & medicinal chemistry letters,
Junhao Xing, and Qing Li, and Shengping Zhang, and Haomiao Liu, and Leilei Zhao, and Haibo Cheng, and Yuan Zhang, and Jinpei Zhou, and Huibin Zhang
Pharmacophore- based virtual screening, 3D- QSAR, molecular docking approach for identification of potential dipeptidyl peptidase IV inhibitors.
April 2021, Journal of biomolecular structure & dynamics,
Junhao Xing, and Qing Li, and Shengping Zhang, and Haomiao Liu, and Leilei Zhao, and Haibo Cheng, and Yuan Zhang, and Jinpei Zhou, and Huibin Zhang
Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (part I): virtual screening and activity assays.
January 2012, PloS one,
Junhao Xing, and Qing Li, and Shengping Zhang, and Haomiao Liu, and Leilei Zhao, and Haibo Cheng, and Yuan Zhang, and Jinpei Zhou, and Huibin Zhang
Dipeptidyl peptidase IV inhibitors.
June 2002, IDrugs : the investigational drugs journal,
Junhao Xing, and Qing Li, and Shengping Zhang, and Haomiao Liu, and Leilei Zhao, and Haibo Cheng, and Yuan Zhang, and Jinpei Zhou, and Huibin Zhang
Synthesis and biological evaluation of homopiperazine derivatives with beta-aminoacyl group as dipeptidyl peptidase IV inhibitors.
December 2008, Bioorganic & medicinal chemistry letters,
Junhao Xing, and Qing Li, and Shengping Zhang, and Haomiao Liu, and Leilei Zhao, and Haibo Cheng, and Yuan Zhang, and Jinpei Zhou, and Huibin Zhang
Design, Synthesis and Biological Evaluation of Spiro Cyclohexane-1,2- Quinazoline Derivatives as Potent Dipeptidyl Peptidase IV Inhibitors.
January 2019, Mini reviews in medicinal chemistry,
Copied contents to your clipboard!